Phase 3 Psoriasis Trial, Recruiting NCT06979453 Sponsor: Bristol-Myers Squibb Condition: Psoriasis
Back to Psoriasis

Phase 3 Psoriasis Trial, Recruiting

NCT06979453
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have had stable plaque psoriasis for 6 months or longer before the screening visit.
  • Your psoriasis is rated as moderate to severe based on three measurements taken at your screening visit and first study day: a skin scoring system called PASI (score of 12 or higher), a doctor's overall rating of your skin (score of 3 or higher), and psoriasis covering at least 10% of your body surface area.
  • If you were born female, you are eligible if you are not pregnant or breastfeeding, and either cannot become pregnant, or are using a highly effective form of contraception during the study and for at least 3 days after finishing the study treatment, and agree not to donate eggs during that same period.

Who may not be able to join:

  • You weigh less than 30 kg (about 66 lbs) at the time of screening or on the first study day.
  • You have a type of psoriasis other than plaque psoriasis (such as guttate, pustular, or others), or another skin condition that could affect how your skin is assessed during the study.
  • You were hospitalised for a serious bacterial, fungal, or viral infection requiring IV antibiotics or antiviral treatment within the past 60 days.
  • You have had any untreated bacterial infection within the past 60 days.
  • You have an ongoing long-term bacterial infection, such as chronic kidney, bone, or lung infections.
  • You have active herpes, active tuberculosis, hepatitis B, hepatitis C, or HIV infection (confirm with trial site for full details).
  • You have received a live vaccine or BCG vaccine within the past 60 days, or plan to receive one during the study or within 60 days of finishing the study treatment.
  • You have previously taken the drug deucravacitinib.
  • You are currently taking certain medications that are not allowed in this trial (confirm with trial site for the full list).
  • You have abnormal laboratory test results that meet the study's exclusion criteria (confirm with trial site for specifics).
  • You have a serious or unstable health condition affecting organs such as the kidneys, liver, lungs, heart, or nervous system, or have an active infection that the study doctor believes would put you at significant risk.
  • You have been diagnosed with cancer or a blood/lymph system disease within the past 5 years.
  • There may be additional eligibility requirements not listed here (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
3 December 2025
Est. completion
12 October 2029

Where this trial is recruiting

🇦🇷 Argentina 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇳 China 🇨🇴 Colombia 🇩🇪 Germany 🇭🇺 Hungary 🇮🇹 Italy 🇲🇽 Mexico 🇵🇱 Poland Puerto Rico 🇷🇴 Romania 🇪🇸 Spain 🇹🇼 Taiwan 🇺🇸 United States

Primary endpoints

Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75); Number of participants achieving a static Physicians Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov